bioRxiv Science⌕ Search

Biology subjects

Rauh, J.

Publications and source records attributed to Rauh, J..

2 recordsLinked to original sources

Expectation of mood improvement entails resource-dependent downregulation of negative inputs

BackgroundClinical trials of antidepressants show improvements in placebo groups of up to 80% compared to the real treatment arm. The mechanism underlying this clinically important effect has been linked to expectation induced goal-directed control. Here, we investigated how cognitive resources influence the effects of positive expectations on emotional processing. MethodsForty-nine healthy volunteers participated in a cross-over fMRI study, in which expectancy of positive emotional changes was induced by an alleged oxytocin nasal spray combined with verbal instruction. Participants performed a spatial cueing paradigm that manipulated the attention to emotional face distractors in the scanner and were characterized regarding their general ability to control attention. ResultsBehavioral findings showed placebo treatment to improve mood and to reduce distractibility by fearful over happy faces, specifically when more attentional resources were available to process faces. This aligned with neural changes in activation and functional coupling in lateral prefrontal-limbic networks indicating an expectation induced top-down regulation of aversive inputs. In addition, behavioral effects and prefrontal-parietal engagement directly correlated with trait ability to control attention. ConclusionsOur data show that placebo treatment combined with verbal instruction alone can improve mood and recruit top-down attentional selection. Changes in emotional processing critically depended on attentional context and individual control ability (i.e., contextual and general resources). These findings may be particularly relevant in patients with major depressive disorder, who often demonstrate a negativity bias and in whom placebo effects by verbal instructions alone may be limited due to reduced cognitive control capacity.

neuroscience↗

Glycine attenuates impairments of stimulus-evokedgamma oscillation in the ketaminemodel of schizophrenia

Although a substantial number of studies suggests some clinical benefit concerning negative symptoms in schizophrenia through the modulation of NMDA-receptor function, none of these approaches achieved clinical approval. Given the large body of evidence concerning glutamatergic dysfunction in a subgroup of patients, biomarkers to identify those with a relevant clinical benefit through glutamatergic modulation are urgently needed. A similar reduction of the early auditory evoked gamma-band response (aeGBR) as found in schizophrenia patients can be observed in healthy subjects in the ketamine-model, which addresses the putative excitation / inhibition (E/I) imbalance of the diseases. Moreover, this change in gamma-band oscillations can be related to the emergence of negative symptoms. Accordingly, this study investigated whether glycine-related increases of the aeGBR accompany an improvement concerning negative symptoms in the ketamine-model. The impact of subanesthetic ketamine doses and the pretreatment with glycine was examined in twenty-four healthy male participants while performing a cognitively demanding aeGBR paradigm with 64-channel electroencephalography. Negative Symptoms were assessed through the Positive and Negative Syndrome Scale (PANSS). Ketamine alone caused a reduction of the aeGBR amplitude associated with more pronounced negative symptoms compared to placebo. Pretreatment with glycine attenuated both, the ketamine-induced alterations of the aeGBR amplitude and the increased PANSS negative scores in glycine-responders, classified based on relative aeGBR increase. Thus, we propose that the aeGBR represents a possible biomarker for negative symptoms in schizophrenia related to insufficient glutamatergic neurotransmission. This would allow to identify patients with negative symptoms, who might benefit from glutamatergic treatment.

neuroscience↗